Great progress has been made in understanding the HCV genome and its molecular
virology. This understanding has culminated in the development of direct-acting antiviral …

About 2% of the world's population is estimated to be chronically infected with hepatitis C
virus (HCV). These chronic carriers are at risk of developing liver cirrhosis and its …

Combinations of direct‐acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the
majority of treatment‐naïve patients. Mass treatment programs to cure HCV in developing …

Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If
untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure …

Sofosbuvir is the first-in-class NS5B nucleotide analogues to be launched for hepatitis C
virus (HCV) treatment. Its viral potency, pangenotypic activity and high barrier to resistance …

Hepatitis C virus (HCV) infection is a major global health problem that continues to grow with
an estimated 170 million people infected. The consequences of chronic infection can …

Due to shared routes of transmission, acute and chronic infection with hepatitis C virus is
common among persons living with HIV infection in many regions of the world. In the era of …

A substantial proportion of individuals with chronic hepatitis C virus (HCV) are co-infected
with human immunodeficiency virus (HIV). Co-infected individuals are traditionally …

Objectives: To review the pharmacology, efficacy, and safety of ledipasvir-sofosbuvir for the
treatment of chronic hepatitis C virus (HCV). Data Sources: A literature search through …

Hepatitis C infection can lead to cirrhosis and hepatocellular carcinoma and it is an
important cause of mortality and morbidity. Achieving a sustained virological response has …